Abstract Development and Phase 3 testing of the most advanced malaria vaccine, RTS,
S/AS01, indicates that malaria vaccine R&D is moving into a new phase. Field trials of …

Abstract The Malaria Vaccine Symposium occurred at Johns Hopkins University in
Baltimore, MD, USA on April 25th, 2017, coinciding with World Malaria Day and the WHO …

In 2013 there were an estimated 584,000 deaths and 198 million clinical illnesses due to
malaria, the majority in sub-Saharan Africa. Vaccines would be the ideal addition to the …

Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Developing an …

The recent availability of significantly increased levels of funding for unmet medical needs in
the developing world, made available by newly created public-private-partnerships, has …

Despite recent progress in reducing deaths attributable to malaria, it continues to claim
approximately 500,000 lives per year and is associated with approximately 200 million …

Although vaccines would be the ideal tool for control, prevention, elimination, and
eradication of many infectious diseases, developing of parasites vaccines such as malaria …

Vaccines are the most powerful public health tools mankind has created, but malaria
parasites are bigger, more complicated, and wilier than the viruses and bacteria that have …

Malaria is a major cause of morbidity and mortality. Immunity is acquired but is suboptimal,
being slow to develop and incomplete. An inadequate understanding of natural immunity …

The development and implementation of a malaria vaccine would constitute a major
breakthrough for global health. Recently, numerous new candidates have entered clinical …